STTR Solutions to Enable Population Genomic Screening (R41/R42 Clinical Trial Optional)
ID: 356109Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356109

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-262.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity through the Small Business Technology Transfer (STTR) program, specifically targeting solutions to enable population genomic screening for actionable genomic conditions in primary care settings. This initiative aims to solicit applications from small businesses to develop innovative and commercializable products that enhance genomic screening efforts, addressing the need for effective educational programs, efficient workflows, and decision support systems for primary care providers. Eligible U.S. small businesses can apply for grants of up to $400,000 for Phase I and $2,150,000 for Phase II projects, with applications accepted from November 1, 2024, to December 3, 2024. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-262-Full-Announcement.html
    Please provide the text you'd like summarized.
    PAR-24-262.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and the National Human Genome Research Institute (NHGRI), is soliciting applications for the STTR Grant titled "Solutions to Enable Population Genomic Screening" (R41/R42) aimed at developing innovative solutions for genomic screening in primary care settings. Eligible small businesses can apply for up to $400,000 for Phase I and $2.15 million for Phase II awards, with application deadlines set for December 2, 2024. This initiative seeks to address barriers to genomic screening and improve education and workflows for primary care providers, while emphasizing the importance of community engagement in genomic research.
    Similar Opportunities
    SBIR Solutions to Enable Population Genomic Screening (R43/R44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "SBIR Solutions to Enable Population Genomic Screening," aimed at soliciting Small Business Innovation Research (SBIR) grant applications from U.S. small businesses. The objective of this initiative is to develop innovative solutions that facilitate population genomic screening for common, actionable genomic conditions within primary care settings, addressing significant barriers such as logistical challenges, provider education, and follow-up procedures. This program is crucial for enhancing the readiness of primary care providers to manage genomic screening, particularly for conditions like hereditary breast cancer and Lynch syndrome. Grants of up to $400,000 are available for Phase I applications, with Phase II grants potentially reaching $2.15 million. Interested applicants should note that the submission window opens on November 1, 2024, with a deadline for applications set for December 2, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Population Genomic Screening in Primary Care Cooperative Agreement (U01 - Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for a pilot program focused on Population Genomic Screening in Primary Care, designated as RFA-HG-24-021. This initiative aims to implement and evaluate screening for common genomic conditions, particularly targeting diverse populations and addressing health disparities, with a goal of enrolling approximately 5,000 patients per Clinical Group. The program emphasizes the importance of community engagement, establishing screening protocols, and ensuring follow-up care, while collaborating with a Coordinating Center and a Sequencing Center to integrate genomic screening into primary care settings. The total funding available is approximately $3.85 million, distributed across 4-5 awards over five years, with applications due by December 2, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Population Genomic Screening in Primary Care Sequencing Center (U01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is soliciting applications for the "Population Genomic Screening in Primary Care Sequencing Center (U01 - Clinical Trial Optional)" grant, aimed at establishing a Sequencing Center to support a new population screening network. This initiative focuses on providing genomic sequencing services for 20,000 study participants, particularly targeting actionable conditions identified by the CDC, such as hereditary breast and ovarian cancer and Lynch syndrome, while ensuring inclusive recruitment from health disparity populations. The program emphasizes collaboration with community stakeholders and primary care providers to enhance genomic testing and follow-up care, ultimately aiming to integrate genomic medicine into primary care and address health disparities. Interested applicants should note that the total budget for the first year is $600,000, with escalating costs for subsequent years, and the application deadline is December 2, 2024. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-24-023.html.
    Population Genomic Screening in Primary Care Coordinating Center(U01 -Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is soliciting applications for a Cooperative Agreement to establish a Coordinating Center focused on population genomic screening in primary care settings. This initiative aims to evaluate and implement screening for 4-7 common genomic conditions, emphasizing community engagement and the integration of healthcare equity, particularly for underserved populations. The program, managed by the National Human Genome Research Institute (NHGRI), seeks to develop frameworks for effective genomic screening practices while adhering to NIH’s data sharing and clinical trial registration policies. Interested applicants can access the full announcement at NIH Grants, with a funding commitment of $5.75 million over five years and an application deadline of December 2, 2024. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the PHS 2024-2 Omnibus Solicitation for Small Business Technology Transfer (STTR) grant applications, inviting eligible U.S. small businesses to submit proposals that include at least one clinical trial. This funding opportunity aims to support research and development projects that align with the scientific missions of participating NIH Institutes and Centers, emphasizing the importance of innovation in health-related technologies. Eligible applicants must be U.S.-based small businesses with majority ownership by U.S. citizens or resident aliens, and the grants provide funding caps of up to $306,872 for Phase I and $2,045,816 for Phase II projects. Interested parties should note that the application deadline is April 5, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the PHS 2024-2 Omnibus Solicitation for Small Business Technology Transfer (STTR) Grant Applications, inviting eligible U.S. small businesses to submit proposals for innovative projects that align with NIH's research and development mission. This funding opportunity, identified as PA-24-247, specifically excludes clinical trials and aims to foster collaboration between small businesses and research institutions to advance technology development in health-related fields. Eligible applicants must be for-profit small businesses based in the U.S., with budget limits set at $306,872 for Phase I and $2,045,816 for Phase II awards. The application deadline is April 5, 2025, with an initial submission date of September 5, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed)" aimed at stimulating innovation in the implementation and sharing of genomic information in clinical care across diverse populations. This initiative encourages applications for small research projects that explore the integration of genomic data into clinical practice, assess barriers to implementation, and develop innovative data analysis techniques, particularly focusing on underrepresented populations in genomic research. The maximum budget for each application is $50,000 over a two-year period, with a total funding expectation of approximately $150,000 for FY 2024. Interested applicants must submit their proposals by February 12, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), in collaboration with the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA), has announced the PHS 2024-2 Omnibus Solicitation for Small Business Innovation Research (SBIR) Grant Applications. This funding opportunity invites eligible U.S. small businesses to submit applications for Phase I, Phase II, Fast-Track, and Direct to Phase II projects that align with the research missions of the NIH, CDC, and FDA, with a focus on stimulating technological innovation and commercialization of federal R&D investments. Notably, applications must not include clinical trials, and funding levels are capped at $306,872 for Phase I and up to $2,045,816 for Phase II, with a submission deadline of April 5, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Advancing Genomic Medicine Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Genomic Medicine Research (R21 Clinical Trial Optional)" aimed at stimulating innovative research in the integration of genomic information into clinical care, particularly for populations experiencing health disparities. This initiative encourages proposals that address implementation science, barriers to genomic medicine, and the integration of genomic data with health and social determinants, with a focus on enhancing health equity among underrepresented groups. The grant provides funding up to $250,000, with applications open from November 1, 2023, until the close date of February 11, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    PHS 2024-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) have announced the PHS 2024-2 Omnibus Solicitation for Small Business Innovation Research (SBIR) grant applications, specifically requiring clinical trials. This funding opportunity is aimed at U.S. small businesses with the necessary research capabilities to contribute to the missions of the NIH and CDC, encouraging innovation and the commercial viability of health technologies. Eligible applicants can receive funding up to $306,872 for Phase I and $2,045,816 for Phase II, with a submission deadline of April 5, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PA-24-246.html.